Company: SHPH
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009325
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 2
Chunk 0
---
The
following Management’s Discussion and Analysis of Financial Condition and Result of Operations (the “MD&A”)
should be read in conjunction with our unaudited financial statements and the related notes thereto included elsewhere in this
Quarterly Report and our financial statement and related notes contained in our annual report on Form 10-K for the fiscal year ended
December 31, 2024. The MD&A contains forward-looking statements that involve risks and uncertainties, such as statements of our
plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking
statements. When used, the words “believe,” “plan,” “intend,” “anticipate,”
“target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions
(“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain
of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by the forward-looking statements in this report. Our
actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a
result of several factors including, but not limited to, those noted under “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2024. 

We do not undertake any obligation to update forward-looking
statements to reflect events or circumstances occurring after the date of this report, except as required by U.S. federal securities
laws.

Overview

Founded by Georgetown University Medical School faculty
members, Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage pharmaceutical company leveraging our proprietary
technology to develop novel therapies that are designed to cure cancer. Originally formed as Shuttle Pharmaceuticals, LLC in 2012, our
goal is to extend the benefits of cancer treatments by leveraging insights into cancer therapy with surgery, radiation therapy, chemotherapy
and immunotherapy. While there are several therapies being developed with the goal of curing cancer, one of the most effective and proven
approaches to this is radiation therapy (“RT”). We are developing a pipeline of products designed to address the limitations of the current standard of cancer
therapies. We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater
scale than that of the current standard of care.

Operations
to date have focused on continuing our research